Tag: Protagonist Therapeutics Inc

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to Protagonist Therapeutics Inc

-$0.48 Earnings Per Share Expected for Protagonist Therapeutics, Inc. (NASDAQ:PTGX) This Quarter

Added to Collection on: 2021-01-08 06:32:41

Tags for this article:

Economy
Finance
Money
Corporate finance
Stock market
Price?earnings ratio
Stock
Short
Securities research
ANGI Homeservices
Protagonist Therapeutics Inc

Click the tags to see associated articles and topics

View Article Details
The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace ...

Added to Collection on: 2021-03-23 15:33:45

Tags for this article:

Life Sciences
Biotechnology
Industry economics)
COVID-19 drug development
Casirivimab/imdevimab
NASDAQ
Gilead Sciences
BioCryst Pharmaceuticals
Regeneron Pharmaceuticals
Antisense therapy
Novo Nordisk
Protagonist Therapeutics Inc
Oramed Pharmaceuticals Inc.
Nuvation Bio Inc.
Radius Health Inc.
the Endocrine Society
Organogenesis Holdings Inc.
Bristol
Adagene Inc.
Sesen Bio Inc.
TreatmentChiasma, Inc.
Odonate Therapeutics Inc
Finch Therapeutics Group Inc.
Sierra Oncology Inc
MacroGenics Inc.
BioCryst Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc.
Acceleron Pharma Inc.
Harmony Biosciences Holdings Inc.
Reviva Pharmaceuticals Holdings Inc.
Seneca Biopharma Inc.
Aclaris Therapeutics Inc.
Theratechnologies Inc.
SI-BONE Inc.
Instil Bio Inc.
CTI BioPharma Corp

Click the tags to see associated articles and topics

View Article Details
Is PTGX Stock A Buy or Sell?

Added to Collection on: 2021-04-24 21:00:00

Tags for this article:

Finance
Investment funds
Hedge funds
Investment
Alternative investment management companies
Point72 Asset Management
NASDAQ
Citadel LLC
Protagonist Therapeutics Inc

Click the tags to see associated articles and topics

View Article Details
Protagonist Therapeutics Announces Proposed Public Offering of Common Stock

Added to Collection on: 2021-06-14 21:02:47

Tags for this article:

Financial markets
Finance
Financial economics
Initial public offering
Stock market
U.S. Securities and Exchange Commission
Prospectus
Shelf registration
Forward-looking statement
Registration statement
Public offering
Security
Protagonist Therapeutics Inc

Click the tags to see associated articles and topics

View Article Details
The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 ...

Added to Collection on: 2021-06-18 11:46:20

Tags for this article:

Companies
Life Sciences
Industry economics)
Economy of New York City
NASDAQ
Bristol-Myers Squibb
BioNTech
BeiGene
Protagonist Therapeutics Inc
Kindred Biosciences Inc
10x genomics inc
Clearside Biomedical Inc
LeMaitre Vascular Inc.
Portage Biotech Inc.
NovoCure Limited
Natus Medical Incorporated
Bio-Techne Corporation
Citius Pharmaceuticals Inc

Click the tags to see associated articles and topics

View Article Details
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update

Added to Collection on: 2024-05-07 21:40:34

Tags for this article:

Takeda Pharmaceutical Company
Net income
Takeda Pharmaceuticals
Protagonist Therapeutics Inc
IL-17

Click the tags to see associated articles and topics

View Article Details
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of ... - Quantisnow

Added to Collection on: 2024-11-18 21:49:22

Tags for this article:

Autoimmune diseases
Psoriasis
Immunosuppressants
Monoclonal antibodies
Psoriatic arthritis
Ulcerative colitis
Risankizumab
Protagonist Therapeutics Inc

Click the tags to see associated articles and topics

View Article Details
Goldman initiated coverage on Protagonist Therapeutics with a new price target

Added to Collection on: 2024-12-07 01:27:14

Tags for this article:

Evercore
Inter-Services Intelligence
Fireside chats
Protagonist Therapeutics Inc

Click the tags to see associated articles and topics

View Article Details
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

Added to Collection on: 2024-12-19 21:16:02

Tags for this article:

Hepatology
Hepcidin
Iron metabolism
Icotrokinra
Protagonist Therapeutics Inc

Click the tags to see associated articles and topics

View Article Details
Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Price Target at $53.78

Added to Collection on: 2025-01-18 06:31:54

Tags for this article:

Equity securities
Stock market
Corporate finance
Financial capital
Private equity
Stock
Short
Share
Protagonist Therapeutics Inc

Click the tags to see associated articles and topics

View Article Details
Book a Demo